Route 92 lands $100M debt facility from Trinity Capital to scale stroke platform
What's the deal? Route 92 Medical, a Utah-based neurovascular medical technology company, has entered a $100 million senior secured debt facility with Trinity CapitalDealroom has a profile for this one. Try Dealroom →. The financing gives the company capital to meet demand for its stroke-treatment products without immediately raising more equity.
What does Route 92 do? The company builds an integrated neurovascular platform that combines access, delivery, and control to help clinicians reach treatment sites during stroke intervention. Its catheters and systems — including the HiPoint 88, the first super-bore aspiration system with FDA clearance for direct aspiration of large vessel occlusions — are covered by more than 200 issued patents.
Why now? The debt facility lands just six months after Route 92 raised $50 million in growth financing in April 2026, which brought in new investor Sectoral Asset ManagementDealroom has a profile for this one. Try Dealroom → alongside lead investor Novo HoldingsDealroom has a profile for this one. Try Dealroom →. That round followed a $50 million Series F extension in 2024 and an initial $31 million Series F in 2023.
Who's backing it? Trinity Capital provides flexible capital to growth-stage and lower middle market companies across the US and Europe. "Trinity's understanding of the medical technology sector and their confidence in our technology, commercial momentum, and long-term vision make them a valuable partner," said Raj Denhoy, chief financial officer of Route 92 Medical.
By the numbers: At $100 million, the facility ranks among the largest debt rounds for a US health company, sitting in the 96th percentile across more than 4,500 comparable deals.
The signal: Stacking substantial debt soon after an equity raise lets Route 92 extend its runway while scaling commercially. It fits a wider wave of neurovascular funding — from Imperative Care's $100 million note to Cerevasc's $85 million Series C — as investors keep backing stroke-intervention platforms.
Read more: AP News
Image credit: Generated with Gemini
